BioCryst Pharmaceuticals BCRX Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's valuation allowance, deferred tax asset, increase (decrease), amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's valuation allowance, deferred tax asset, increase (decrease), amount?
- BioCryst Pharmaceuticals (BCRX) reported valuation allowance, deferred tax asset, increase (decrease), amount of -$17.06M in Q4 2025.
- How has BioCryst Pharmaceuticals's valuation allowance, deferred tax asset, increase (decrease), amount changed year-over-year?
- BioCryst Pharmaceuticals's valuation allowance, deferred tax asset, increase (decrease), amount decreased by 686.0% year-over-year, from $2.91M to -$17.06M.
- What is the long-term trend for BioCryst Pharmaceuticals's valuation allowance, deferred tax asset, increase (decrease), amount?
- Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's valuation allowance, deferred tax asset, increase (decrease), amount has grown at a 19.9% compound annual growth rate (CAGR), from $47.49M to -$68.22M.
- What does valuation allowance, deferred tax asset, increase (decrease), amount mean?
- Tracks the net change in the valuation allowance held against deferred tax assets, which are assets that may reduce future tax payments. A decrease in this allowance suggests improved confidence in future profitability, while an increase suggests heightened uncertainty. This is a vital metric for assessing the company's ability to utilize tax carryforwards.